

Protocol Review, Development, and Approval Module Resources

Selected References

Filchner, K. (2016). Protocol Review and Approval Process. In A.D. Klimaszewski, M.A. Bacon, E.A. Ness, J.G. Westendorp, & K. Willingberg (Eds.), *Manual for Clinical Trials Nursing* (3rd edition, pp. 141-154). Pittsburgh, PA: Oncology Nursing Society.

Institutional Review Boards, 21 C.F.R. 56 (2015). Retrieved from

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=56&showFR=1&subpartNode=21:1.0.1.1.22.2>

International Conference on Harmonisation of Technical Requirements for Registrations of Pharmaceuticals for Human Use (1997, July 17). *General considerations for clinical trials* (E8).

Retrieved from

http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf

Karp, B.L., & Nussenblatt, R.B. (2012). Writing a protocol. In J.I. Gallin & F.P. Ognibene (Eds.), *Principles and practice of clinical research* (3rd ed., pp. 483–489). Waltham, MA: Elsevier Academic Press. doi:10.1016/B978-0-12-382167-6.00032-1

Madsen, L.T. & Ness, E. (2016). Protocol Development and Response Assessment. In A.D. Klimaszewski, M.A. Bacon, E.A. Ness, J.G. Westendorp, & K. Willingberg (Eds.), *Manual for Clinical Trials Nursing* (3rd edition, pp. 127-140). Pittsburgh, PA: Oncology Nursing Society.

Mitchel, W. & Smith, Z. (2016). Elements of a Protocol. In A.D. Klimaszewski, M.A. Bacon, E.A. Ness, J.G. Westendorp, & K. Willingberg (Eds.), *Manual for Clinical Trials Nursing* (3rd edition, pp. 109-112). Pittsburgh, PA: Oncology Nursing Society.

Protection of Human Subjects, 21 C.F.R. 50 (2015). Retrieved from

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&showFR=1>

Protection of Human Subjects, 45 C.F.R. 46 (2009). Retrieved from

<http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html>

Radioactive Drugs for Certain Research Uses, 21 C.F.R. § 361.1 (2015). Retrieved from

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=361.1>

U.S. Food and Drug Administration. (2006, January). Information sheet guidance for IRBs, clinical

investigators, and sponsors: Significant risk and nonsignificant risk medical device studies. Retrieved

from <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126418.pdf>

U.S. Food and Drug Administration. (2016, January). Payment to research subjects—Information sheet: Guidance for institutional review boards and clinical investigators. Retrieved from

<http://www.fda.gov/regulatoryinformation/guidances/ucm126429.htm>

U.S. Food and Drug Administration. (2012, February). Guidance for IRBs, Clinical investigators, and sponsors IRB continuing review after clinical investigation approval. Retrieved from

<http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM294558.pdf>

U.S. Food and Drug Administration. (2013, August). Guidance for IRBs, clinical investigators, and sponsors—IRB responsibilities for reviewing the qualifications of investigators, adequacy of research sites, and the determination of whether an IND/IDE is needed. Retrieved from

<http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM328855.pdf>

Wichman, A. (2012). Institutional review boards. In J.I. Gallin & F.P. Ognibene (Eds.), *Principles and practice of clinical research* (3rd ed., pp 225–242). Boston, MA: Elsevier Academic Press.

doi:10.1016/B978-0-12-382167-6.00005-9

Human Gene Transfer Resources

National Institutes of Health Office of Biotechnology Activities. (2016, April). NIH guidelines for research involving recombinant or synthetic nucleic acid molecules. Retrieved from

http://osp.od.nih.gov/sites/default/files/resources/NIH_Guidelines.pdf

National Institutes of Health Office of Biotechnology Activities. (2016, April). Frequently Asked Questions about the Registration and Review Process for Human Gene Transfer Protocols. Retrieved from

http://osp.od.nih.gov/sites/default/files/HGT_FAQ%20sheet_508%20complaint.pdf

National Institutes of Health Office of Biotechnology Activities. (n.d.). NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines). Retrieved from

http://osp.od.nih.gov/sites/default/files/HGT_FAQ%20sheet_508%20complaint.pdf

Website: Institutional Biosafety Committee FAQs: <http://osp.od.nih.gov/office-biotechnology-activities/biosafety/institutional-biosafety-committees/faq>